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ABSTRACT
Defects in the mismatch repair protein MSH2
cause tolerance to DNA damage. We report how
cancer-derived and polymorphic MSH2 missense
mutationsaffectcisplatincytotoxicity.Thechemotol-
erance phenotype was compared with the mutator
phenotype in a yeast model system. MSH2 missense
mutations display a strikingly different effect on cell
death and genome instability. A mutator phenotype
does not predict chemotoleranceor vice versa.MSH2
mutationsthatwereidentifiedintumors(Y109C)oras
genetic variations (L402F) promote tolerance to cis-
platin, but leave the initial mutation rate of cells
unaltered. A secondary increase in the mutation
rate is observed after cisplatin exposure in these
strains. The mutation spectrum of cisplatin-resistant
mutators identifies persistent cisplatin adduction as
the cause for this acquired genome instability. Our
results demonstrate that MSH2 missense mutations
that were identified in tumors or as polymorphic
variations can cause increased cisplatin tolerance
independent of an initial mutator phenotype.
Cisplatin exposure promotes drug-induced genome
instability. From a mechanistical standpoint, these
data demonstrate functional separation between
MSH2-dependent cisplatin cytotoxicity and repair.
From a clinical standpoint, these data provide valu-
able information on the consequences of point muta-
tionsforthesuccessofchemotherapyandtheriskfor
secondary carcinogenesis.
INTRODUCTION
Defects in mismatch repair (MMR) proteins promote hered-
itary [hereditary nonpolyposis colorectal cancer (HNPCC)]
and several sporadic forms of cancer (1). The mismatch recog-
nition protein MSH2 and the molecular matchmaker MLH1
are most commonly mutated in MMR-defective tumors. While
many of these mutations result in a truncation and loss of the
proteins, several single point mutations have been identiﬁed
that are believed to equally promote carcinogenesis by estab-
lishing a mutator phenotype.
In addition to the repair of replication errors, MMR proteins
are involved in several other cellular responses. Among these
is the response to DNA damage, such as inﬂicted by most
chemotherapeutic agents. A MMR-dependent induction of
cell cycle arrest and/or apoptosis is observed. Defects in
MMRproteins,therefore, notonlyresultingenomeinstability,
but can also promote tolerance to chemotherapy (2). MMR-
deﬁcient cells show increased survival and resistance to treat-
ment with methylating agents and 6-thioguanine (6-TG). In
addition, an increased tolerance to the common chemothera-
peutic agent cisplatin is observed, which manifests itself in a
2- to 3-fold increase in cell survival after cisplatin exposure
(2). Though MMR proteins recognize cisplatinated DNA
adducts, they are not involved in the repair of this damage
(3). We have recently demonstrated that the repair function of
MSH2isnotrequiredfortheMMR-dependentinductionofcell
death after cisplatin exposure, suggesting an uncoupling of
both events and a direct role for the MMR protein in damage
signaling (4) (F. Salsbury, J. Clodfelter, M. Gentry, T. Hollis
and K. Drotschmann, manuscript in preparation).
Though a complete knockout in MMR results in increased
cisplatin tolerance, it is unknown how single point mutations
in MMR genes affect the response to a chemotherapeutic
agent. This is of particular signiﬁcance, if the missense muta-
tion is identiﬁed in tumor cells.
A drug tolerance phenotype can be associated with
enhanced susceptibility to DNA damage-induced mutations.
As a consequence, MMR-defective cells show a high
spontaneous mutation rate after drug exposure (5). This
acquired genome instability has been attributed to the growth
advantage of MMR-deﬁcient cells after chemotherapeutic
treatment, which results in the expansion of cultures of
repair-defective cells and the accumulation of mutations in
downstream genes. This acquiredmutatorphenotypemay con-
tribute to the development of therapy-related, secondary
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doi:10.1093/nar/gki646tumors, as was suggested for the development of acute
myeloid leukemia (AML). Fifty percent of therapy-related
AML cases show microsatellite instability, a hallmark of
MMR defects. Such cases are predominantly observed after
chemotherapeutic treatment of primary malignancies with
methylating agents, or the treatment of non-malignant cells
with immunosuppressiva after organ transplantation (5). Even
moderate alkylation tolerance can predispose to AML via
MMR defects. It is currently unknown whether exposure to
other agents contributes to increased mutagenesis in a similar
way. Several single MSH2 mutations were identiﬁed in tumor
cells. It is unknown how these point mutations affect the
development of a supermutator phenotype.
Here, we analyzed single point mutations in MSH2 that
are homologous to those identiﬁed in tumors, or described
as polymorphisms, for their effect on cytotoxicity in response
to cisplatin and the development of acquired genome instab-
ility. We demonstrate that MSH2 missense mutations decrease
cytotoxicity and confer increased tolerance. This tolerance
phenotype is independent of a mutator phenotype. Cisplatin
exposure of cells harboring MSH2 mutations promotes the
development of acquired genome instability, independent of
an initial cisplatin-independent mutator phenotype. This drug-
induced mutator phenotype may be caused by unprocessed
cisplatin adducts in DNA. Given the fact that the mutations
analyzed here were identiﬁed in tumor cells or described as
polymorphisms, these data have important implications for
the choice and efﬁcacy of cancer treatment.
MATERIALS AND METHODS
Strains
All yeast strains used in this study are isogenic and have been
described previously (4,6). Expression plasmids have been
described previously (4,6). Mutations were introduced by
site-directed mutagenesis (Stratagene).
Immunoblot analysis
Cells were grown in synthetic media lacking uracil overnight
at 30 C and harvested by centrifugation. Cell lysis was
achieved by the addition of glass beads, and debris was
pelleted by centrifugation. The protein concentration of the
supernatant was determined and equal amounts separated by
gel electrophoresis. Blot analysis was performed using a
polyclonal anti-Msh2 antibody (6).
Genetic assays
Treatment with cisplatin and cell survival assays were per-
formed as described previously (4). The IC50 (concentration
resulting in 50% cell death) values and conﬁdence limits were
obtained as described previously (4). Brieﬂy, overnight cul-
tures of Saccharomyces cerevisiae strains grown in selective
media (lacking the respective amino acid for the selection of
the ARS-CEN plasmid) were split in half and diluted. At early
log phase, one half of the cultures obtained indicated concen-
trations of cisplatin in selective media. After incubation with
(and without) cisplatin for 16–24 h, appropriate dilutions were
plated onto selective media without drug and cells allowed
to grow at 30 C for 4 days. Wild-type strains were grown in
complete media containing all essential amino acids. Colonies
were counted, and the number of colonies after treatment was
compared with the total number of colonies without drug and
expressed as percent survival. The IC50 was determined by
ﬁtting parametric response curves using standard least-squares
linear models with both linear and quadratic terms for cisplatin
dose. For each clone, the following model was ﬁtted:
Yi =b 0 +b 1x +b 2x
2 +e i, where Yi is the % cell death; b0,
b1 and b2 are standard least-squares regression coefﬁcients; x
is cisplatin dose in mM; and ei is the usual normal error term
for the linear regression model. After ﬁtting a model for each
cell type, the quadratic formula and estimated regression coef-
ﬁcients were used to solve for x such that Y = 50%. Mutation
rate determinations based on ﬂuctuation tests have been
described previously (4,6). For the determination of the
CAN1 gene mutations after cisplatin exposure, cells were
exposed to the indicated cisplatin concentration overnight
and plated onto canavanine containing media. Individual col-
onies were isolated and the CAN1 gene PCR-ampliﬁed using
primers 50-CAG ACT TCT TAA CTC CTG-30 and 50-GGA
ATG TGA TTA AAG GTA ATA AAA CG-30. The PCR
product was sequenced using primers Can-SF-1: 50-ATT
CTG TCA CGC AGT CCT; Can-SF-2: GAA CTA GTT
GGT ATC ACT; Can-SF-3: CTC AAT CTC GCA CAT
CAG; Can-SR-1: TGT CTC CAT GTA AGC CAA; Can-
SR-2: ATA TTA TAC CTG GAC CCC; Can-SR-3: ATG
AAA AGA CCT GTA CCA. Sequences were compared
with the wild-type CAN1 sequence.
RESULTS
Cisplatin cytotoxicity in strains harboring MSH2
missense mutations
We determined the effect of single MSH2 point mutations on
cisplatin cytotoxicity and addressed its correlation with a
mutator phenotype in a yeast model system (6). Numerous
MSH2 missense mutations have been identiﬁed in sporadic
and hereditary tumors of different origin. In addition, an
increasing number of amino acid alterations in MSH2 have
been described as genetic variants (6–8) (http://www.insight-
group.org; http://www.nfdht.nl). Based on a sequence align-
ment of MutS proteins (Figure 1A) (9), homologous mutations
were introduced into the yeast MSH2 gene (6). All mutants
produceproteinlevelsindistinguishablefromwild-typeMSH2
(Figure 1B). Figure 1C shows the location of mutations on the
MutS crystal structure. MSH2 missense mutations are ran-
domly distributed over the entire protein. Mutations Y109C
(Figure 1D, blue) and R542P are located in the DNA-binding
domains,whileG770Raffects theATPasedomain(red).Other
mutations affect regions that are involved in intra- and
interdomain contacts (e.g. L402F, Figure 1D).
The effects of MSH2 mutations on cisplatin cytotoxicity
were analyzed in a yeast model system (4). Dose-dependent
cell survival determines the effect of individual mutations (4).
The IC50 was used as an indicator for the effect of a particular
mutation on cisplatin cytotoxicity. A complete knockout in
MSH2resultsin the previouslydescribed,typically2-to3-fold
increase in tolerance of cells to cisplatin treatment (Table 1,
2.4-fold). The effect on cytotoxicity was compared with
altered repair activity, as determined in the CAN1 reporter sys-
tem (4). This reporter monitors any mutations that inactivate
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IC50 [mM cisplatin] Mutation rate in CAN1 [10
 6]
MSH2 allele IC50 CL RR MR CL RR
msh2D 360 330–390 2.4 15 11–19 32
MSH2 wt 150 130–170 1 0.47 0.37–0.66 1
Separation-of-function: increased cisplatin tolerance without a mutator phenotype
Y109C 290 240–340 1.9 1.2 0.25–4.1 2.6
L402F 250 190–310 1.7 3.6 1.4–5.5 7.7
Separation-of-function: increased mutator phenotype with unaltered cisplatin cytotoxicity
G770R 130 120–140 0.87 19 14–25 40
R371S 180 170–190 1.2 39 20–54 83
P640L 200 130–260 1.3 24 20–34 51
Increased cisplatin tolerance and a mutator phenotype
R542P 300 250–340 2 19 13–26 40
No/weak effect on cisplatin cytotoxicity and mutation rate
E194A 130 101–150 0.87 4.4 2.4–7.2 9.4
CL, 95% confidence limits; RR, relative rate (bold); compared with wild type (underlined); MR, mutation rate.
Figure1.MissensemutationsinMSH2.(A)Alignmentofhuman(hMSH2)andyeast(yMsh2)aminoacidsequencesindicatingthelocationofpointmutations.Stars
above the alignment indicate the side of mutation (bold); underneath the diagram single point mutations in the yeast MSH2 protein that were analyzed here are
indicated. (B) Western blot analysis demonstrating the expression of mutant MSH2 genes. The corresponding MSH2 mutation is indicated. (C) Structure of the
MSH2-homologoussubunitBofE.coliMutSincomplexwithmismatchedDNA(36)withtheaminoacidalterationsindicatedathomologoussides.Coloringdepicts
the domain structure of the protein, with blue: mismatch binding (I), green: connector (II), yellow: core (III), orange: clamp (IV) and red: ATPase/dimerization (V)
domains.Aminoaciddesignationsareyeastnumbers.(D)Close-upviewofthelocationofY109inthemismatch-bindingdomainI,andL402inthecoredomainIII,
respectively.
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increase in the mutation rate (Table 1). Non-overlapping, 95%
conﬁdence limits between different strains indicate statistical
signiﬁcance.
Most prominent changes in cisplatin cytotoxicity are
observed with mutations Y109C and L402F (Table 1). Muta-
tion Y109C shows a signiﬁcant increase in the tolerance to
cisplatin exposure. The IC50 of 290 mM has overlapping con-
ﬁdence limits with the knockout strain, suggesting that the
response in both strains is indistinguishable (Table 1). In con-
trast, this mutation does not result in a mutator phenotype,
and the mutation rate is not signiﬁcantly different from the
wild-type strain (2.6-fold increase, with overlapping conﬁd-
ence limits to wild type). The Y109C mutation is homologous
to the Y103C mutation in human MSH2, which was identiﬁed
in association with HNPCC (http://www.insight-group.org;
http://www.nfdht.nl).
The L402F mutation results in an increase in cisplatin tol-
erance, which is signiﬁcantly different from the wild-type
response (Table 1, IC50 of 250 mM). In contrast, the mutant
strain shows a weak mutator phenotype (7.7-fold elevated
over wild type; compared with 32-fold for the knockout
strain). The corresponding mutation L390F in human
MSH2 was described as a genetic variation in the general
population with an allele frequency of 0.005 (8).
These effects are in contrast to consequences observed for
MSH2-G770R. The cisplatin cytotoxicity in this strain is
unaltered when compared with the wild type (130 mM com-
pared with 150 mM for the wild-type strain). The G770R
mutation confers a strong mutator phenotype (40-fold) that
is indistinguishable from a complete knockout strain
(Table 1, 32-fold). G770R affects a residue in the ATPase
domain of MSH2 (Figure 1C). The corresponding mutation
in human MSH2 is associated with HNPCC (http://www.
insight-group.org; http://www.nfdht.nl). Similarly, mutations
R371S and P640L do not signiﬁcantly alter cisplatin cytotox-
icity (1.2- and 1.3-fold, respectively, with overlapping conﬁd-
ence limits with wild type). The mutation rate is considerably
elevated in both strains (83- and 51-fold, respectively, Table
1). The homologous human mutations are found in association
with HNPCC [(10,11), http://www.insight-group.org; http://
www.nfdht.nl].
Mutation R542P signiﬁcantly increases both cisplatin res-
istance (IC50 of 300 mM with conﬁdence limits overlapping
with the msh2D strain) and the mutation rate of the cell
(40-fold; Table 1). The homologous mutation was identiﬁed
in a patient with ovarian cancer suggestive of HNPCC (12).
Mutation E194A does not signiﬁcantly alter cisplatin cytotox-
icity and displays a weak mutator phenotype.
These data demonstrate that single point mutations in
MSH2 can alter cisplatin cytotoxicity. Individual mutations
affect the cytotoxicity differently. No obvious association
with the location of the mutation in the protein is observed.
The chemotolerant phenotype is not correlated with a mutator
phenotype.
A cisplatin-induced mutator phenotype in strains
harboring Y109C and L402F
We next determined whether the presence of a single point
mutation in MSH2 promotes the development of acquired
genome instability after cisplatin exposure. The mutation
rate of cisplatin-tolerant clones was analyzed in the CAN1
reporter system. The mutator phenotype of cisplatin-tolerant
clones (Table 2) was compared with the mutation rate without
exposure to identify a cisplatin-induced change (Table 1).
Exposure of the wild type strain to cisplatin does not alter
the mutation rate (mutation rates 0.47 and 0.37 · 10
 6,
respectively, Table 2). Mutations MSH2-Y109C and L402F,
respectively, which confer cisplatin tolerance and no or a
weak mutator phenotype in the absence of cisplatin exposure
(Table 1), show a signiﬁcant cisplatin-induced mutator pheno-
type. After drug exposure, cisplatin-tolerant clones harboring
MSH2-Y109C show a signiﬁcant mutator phenotype that is
5.2-fold elevated when compared with the initial mutation
rate (compare 6.2 with 1.2 · 10
 6; Table 2). This acquired
genome instability results in an overall 13-fold elevation in
the mutation rate when compared with the wild-type rate
(without exposure). MSH2-L402F weakly elevates the muta-
tionrateintheabsenceofcisplatin(3.6 · 10
 6;7.7-foldabove
wild-type levels; Tables 1 and 2). Cisplatin-resistant clones of
this strain display a signiﬁcant 2.5-fold increase in the muta-
tion rate when compared with this initial rate. This causes an
overall 19-fold elevation, resulting in a mutation rate
that is indistinguishable from a complete knockout strain
(compare 9 · 10
 6 for L402F with 15 · 10
 6 for msh2D,
with overlapping conﬁdence limits, Table 2). Both strains
harboring Y109C and L402F, respectively, promote acquired
genome instability.
The already strong mutator phenotype of cells harboring
G770R (Table 1) is further elevated by exposure to cisplatin
and reaches a mutation rate that goes beyond the knockout
Table 2. Drug-induced supermutator phenotype
Without exposure After cisplatin (340 mM)
MR 10
 6 CL 10
 6 RR MR 10
 6 CL 10
 6 RR
msh2D 15 11–19 32 ND
MSH2 wt 0.47 0.37–0.66 1 0.37 0.31–0.45 0.8
Y109C 1.2 0.25–4.1 2.6 6.2 5.9–9.6 13 (5.2x)
L402F 3.6 1.4–5.5 7.7 9.0 7.5–12 19 (2.5x)
G770R 19 14–25 40 41 26–47 87 (2.1x)
R371S 39 20–54 83 29 26–43 62
P640L 24 20–34 51 24 20–30 51
R542P 19 13–26 40 24 19–29 51
E194A 4.4 2.4–7.2 9.4 6.5 4.6–7.4 14
MR, mutation rate; CL, 95% confidence limits; RR, relative rate (bold); compared with wild type (underlined).
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Table 2). None of the strains harboring any of the other muta-
tions, independent of their initial mutation rate or cisplatin
tolerance, promotes a cisplatin-induced mutator phenotype.
Themutationalspectrumofacquiredgenomeinstability
To analyze whether the cisplatin-induced genome instability
observed for mutations Y109C and L402F is due to an accu-
mulation of unprocessed, cisplatin-induced mutations, the
mutation spectrum was determined. Individual, cisplatin-
tolerant mutator clones from strains harboring either muta-
tion (Table 2) were isolated. The reporter gene CAN1 was
sequenced to determine the nature of inactivating mutations.
The sequence was compared with the wild-type sequence for
the CAN1 gene. In addition, the mutation spectrum was com-
pared with the published mutation spectrum of an msh2D
strain without drug exposure (13). The overall distribution
of insertion/deletion and base substitution mutations is
unaltered when compared with the described spectrum for
the msh2D strain (13). A total of 83 and 75% of cisplatin-
resistant clones of cells harboring MSH2-Y109C and L402F,
respectively, are insertion/deletions [as compared with 85%
for the msh2D strain (13)]. The spectrum of mutations preval-
ent in Y109C or L402F expressing clones without cisplatin
exposure is indistinguishable from the MSH2-defective strain.
One nucleotide deletions in a stretch of six adenines, and a 1 nt
addition in a run of six thymidines are observed (data not
shown). These mutations are commonly found in MSH2-deﬁ-
cient strains (13). The mutation spectrum of cisplatin-tolerant
cells harboring either one of the point mutations shows con-
siderable differences (Table 3). Mutations in previously
undescribed sequence contexts are observed. The spectrum
of cisplatin-resistant clones of Y109C primarily shows a 1
nt deletion in two adjacent guanines. In addition, the deletion
of 4 nt (DAAGT) is observed. Both sequence contexts are
targets for the adduction with cisplatin, which crosslinks
two adjacent purines, primarily GpG, but also ApG. Similarly,
mutation L402F generates a 1 nt deletion within two adjacent
guanines, though at a different site. An additional thymine
deletion is observed directly downstream of a guanine dinuc-
leotiderepeat (Table 3).Theonlybase substitutionobserved in
the L402F mutant strain is a G to T mutation that alters the
cisplatin target GA to a TA, consistent with errors occurring at
the site of the cisplatin-intrastrand crosslink. These data dem-
onstrate that cisplatin-resistant clones of MSH2-Y109C and
L402F accumulate mutations at sites of potential cisplatin
adduction.
DISCUSSION
We demonstrate that single point mutations in the MMR pro-
tein MSH2 have the potential to signiﬁcantly increase toler-
ance to the chemotherapeutic agent cisplatin and promote a
cisplatin-induced mutator phenotype.
Amino acid alterations MSH2-Y109C and L402F represent
separation-of-function mutants that demonstrate that (i) single
point mutations can increase cisplatin tolerance and cell sur-
vival after exposure to cisplatin; (ii) this cisplatin tolerance is
independent of a mutator phenotype; and (iii) exposure of
these mutants to cisplatin induces a mutator phenotype.
The missing correlation between genome instability and
increased cisplatin tolerance demonstrates that the MSH2-
dependent cell death pathway that is initiated after exposure
to cisplatin is functionally independent of repair events initi-
ated by the protein. This is supported by earlier ﬁndings that
showed that a mutation in the ATPase domain of MSH2 leaves
the cell MMR defective, but does not alter cisplatin cytotox-
icity in both a yeast and mouse model (4,14). Similarly, a point
mutation in yeast and mouse MSH6 showed separation-of-
function between repair and damage response (15).
A complete MMR deﬁciency results in a weak, 2- to 3-fold
increase in cisplatin tolerance, which is observed in all
tested systems [Table 2; (4,16–18); F. Salsbury, J. Clodfelter,
M. Gentry, T. Hollis and K. Drotschmann, manuscript in pre-
paration].Thoughanapparentlysmalleffect,itresultsinclonal
selectionof MMR-defective cells and contributes tosecondary
tumor growth (19). Furthermore, this chemotolerant pheno-
type has been observed consistently in all MMR-deﬁcient cell
lines tested to date. Both observations point to the biological
signiﬁcance of this chemotolerant phenotype (2).
It was previously shown that exposure of MMR-deﬁcient
cancer cell lines to chemotherapeutic agents, such as methyl
methanesulfonate (MMS), MNNG or 6-TG (20,21), results
in induced genome instability. We demonstrate that different
MSH2 point mutations can promote the development of a
cisplatin-induced mutator phenotype (Table 2). An increased
cisplatin tolerance phenotype is not sufﬁcient for or predictive
of the induced genome instability phenotype. This is evident
from the cisplatin-induced mutator phenotype observed for
G770R. This mutation does not promote cisplatin tolerance,
but shows a signiﬁcant increase in the mutation rate after
cisplatin treatment, despite the already high initial mutation
rate (Table 2). On the other hand, mutation R542P, which
confers a cisplatin tolerance phenotype indistinguishable
fromthe knockoutstrain(Table1)anda strongmutatorpheno-
type, does not promote cisplatin-induced genome instability
(Table 2). Neither an initial mutator nor a cisplatin-tolerant
phenotype appears to be predictive of cisplatin-induced gen-
ome instability. Products of MNNG and 6-TG are suggested
to create mismatches in DNA that are processed by MMR
proteins. Lack of repair or the generation of single-strand
breaks is one hypothesis to explain induced genome instability
in the MMR-deﬁcient cell lines for these types of damage. Our
data demonstrate that the mutagenic effect of chemical expos-
ure can be independent of an initial mutator phenotype, and
thereby appears to be independent of the repair function. In the
case of MMS, the mutagenic effect was attributed to the gen-
eration ofand failureto processing ofabasicsites in the MMR-
defective background. The overall level of increase in the
Table 3. Mutation spectrum in CAN1 of cisplatin-resistant clones
Mutant Insertion/deletion Base substitution
Y109C
DGG G ! GC ! T
DAA 6 ! A5
+TT T3 ! T5
DAAGT
L402F
DGG G ! G TGA ! TTA
DT GGTTA ! GGTA
+TT 6 ! T7
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here (22). The mutation spectrum for MMS-induced genome
instabilityidentiﬁedprimarilytransversions.IncontrasttoMMS,
cisplatin adducts are not subject to BER and are not expected
togenerateabasicsites.Inaddition,ourdatahereidentifyprim-
arily frameshift mutations at target sequences for cisplatin
adduction (Table 3). Both, our study and the one by Glaab
et al. (20) demonstrate that MMR-dependent cytotoxicity and
mutagenicity can function independent from each other.
The MSH2 mutations that promote induced genome instab-
ility are randomly distributed over the protein with no obvious
‘clustering’. Hence, no predictions of their phenotypes can be
made based on the nature of the mutation. We cannot exclude
that the point mutations confer a weak or ‘silent’ mutator
phenotype that will become more important under conditions
when the mutational burden of the cell is increased. Recent
studies suggested that the amount of DNA damage may be
crucial in the response of cells harboring mutated MMR pro-
teins (23). Mutant proteins may retain different capacities for
the processing of different substrates, and a functional ‘dose
response’ may be observed. However, MMR proteins are not
suggested to be involved in the direct repair of cisplatin
adducts (3). If the induced mutator phenotype of MSH2-
Y109C and MSH2-L402F, respectively, was due to a satura-
tion of the (reduced) repair capacity of these mutants after
cisplatin exposure, the mutation spectrum should represent
more random changes in the DNA. Though we observe
some mutations in sequences outside of cisplatin targets,
the overall mutation spectrum is shifted toward cisplatin
target sequences (Table 3). This would suggest that the
induced mutation rate is due to alterations speciﬁc for these
sequences. Together with the cell survival studies (Table 1),
our data suggest that the mutant proteins are unable to elim-
inate damaged cells via a cell death pathway, cisplatin adducts
are retained in the DNA and can be subject for aberrant or
translesion bypass. In addition, mutant proteins may have a
‘hidden’defectintheantirecombinationfunction, which under
massive DNA damage would result in uncontrolled recom-
binational events (see below).
Owing to their ability to recognize DNA damage, MMR
proteins may contribute to replication blockage and thereby
initiate a cell death pathway (2). If the damage-sensing and
signaling function is disrupted, increased translesion bypass
by error-prone polymerases might occur. It was previously
shown that the net bypass of cisplatin adducts is increased
in MMR-deﬁcient cell lines, and that this increased bypass
is correlated with increased drug resistance in these cultures
(24). This observation supports the hypothesis that mutations
that alter the DNA damage-sensing ability of the protein will
prevent blockage and promote increased lesion bypass. This
switch would then result in an increase in the mutational
burden in the cell rather than cell death. Importantly, we
demonstrate here that single point mutations in MSH2,
which are either derived from tumor tissue or were identiﬁed
as polymorphisms, can inﬂuence and promote this effect. The
mutation spectra (Table 3) are consistent with the insertion
speciﬁcity of several of the translesion polymerases shown to
process cisplatin-containing DNA damage (25,26). Poly-
merases b and h were shown to generate mutations that are
identical to the ones determined here. The lack of an efﬁcient
MMR-dependent replication block might result in increased
translesionbypassbyerror-pronepolymerasesandresultinthe
increased mutational burden. The relatively small increase in
the mutation rate may be due to the observation that poly-
merase h can bypass some cisplatin adducts in an error-free
translesion synthesis step (27). In addition, lack of MMR
proteins might provide additional access to the lesion for
the correction of the damage by nucleotide excision repair
(3). The functional implications of the missense mutations
for which a cisplatin-induced mutator phenotype is observed
support this hypothesis. These mutations affect regions
involved in DNA binding or ATPase, or affect structurally
important areas which may have consequences for DNA–
ATP interactions.
Inadditiontotranslesionsynthesis,recombinationbypassof
DNA damage can be initiated. It was previously shown that
low doses of MNNG can induce intrachromosomal recomb-
ination. Zhang et al. (28) demonstrated that MMR proteins
are required for the recombination event. The recombination
event was found to be stimulated by futile repair cycles and
hence requires functional repair activity (28). Our data dem-
onstrate that the repair function of the proteins is not required
for MMR-mediated cisplatin cytotoxicity. The induction of
recombination by futile repair cycles of cisplatin-containing
DNA is hence unlikely.
In response to cisplatin, MMR proteins exhibit an antire-
combination effect; a defect in this mechanism contributes to
increased damage tolerance in MMR-defective tumors (29).
Increased recombinational bypass of cisplatin lesions results
in elevated sister chromatid exchange. This was observed in
MMR-deﬁcient ovarian cancer cell lines (29). However,
another study demonstrated that MMR proteins are not
involved in the generation of chromosomal aberrations
induced by cisplatin (30). No gross rearrangements are
observed after the treatment of cells with cisplatin in our
study (Table 3). In addition, cisplatin-induced recombination
in a mutS strain is indistinguishable from the wild-type
response (31). Until recently, no mutants had been identiﬁed
that would separate the functional requirements for the MMR-
dependent antirecombination effect from those in repair (32).
However, recent studies investigating the MutS antirecom-
bination effect on cisplatinated DNA in Escherichia coli
(23) identiﬁed a MutS mutant that lost this antirecombination
effect. The loss of this effect was associated with increased
cisplatin resistance, but did not affect MNNG sensitivity or
the repair function. Similarly, Durant et al. (29) demonstrated
that MMR proteins in yeast inhibit the recombinational bypass
of cisplatin adducts. Mutants in either rad52 or rad1 reverse
the increased resistance found in the MMR-deﬁcient
strains. Loss of MMR proteins hence abolishes the antirecom-
bination effect in yeast and results in increased RAD52/
RAD1-dependent recombinational bypass of damage.
In the light of our results, mutations L402F and Y109C may
exhibit a (partial) defect in the antirecombination function
of the protein. With increasing concentrations of cisplatin
damage, increased, aberrant recombinational bypass may
be observed. If this was the case, an additional mutation in
recombination would be predicted to reverse the effects
observed for these point mutations. To address this question
and elucidate the precise mechanism(s) behind the results
described here, further biochemical and genetic analyses of
the mutants have been initiated in the laboratory.
3328 Nucleic Acids Research, 2005, Vol. 33, No. 10Different hypotheses have been put forward to address the
mechanism of MMR-dependent damage response. Futile
cycles of repair have primarily been suggestedforthe response
to alkylation damage. This hypothesis is based on the obser-
vation that MMR-dependent cell cycle arrest to alkylation
damage occurs after the second S phase. However, this
observation is largely dependent on the dose of the chemo-
therapeutic agent (2,5). This mechanism requires the repair
function of these proteins.
The concentration-dependent response to MNNG suggested
the different participation of MMR proteins in response path-
ways to different levels of damage. At low dosage, O
6meG/T
mismatches are generated, resulting in delayed response. Pro-
cessing of these mismatches is absolutely dependent on MMR,
which presumably initiates futile cycles of repair. At high
doses of MNNG, DNA damage signaling becomes too
rapid forreplication-association, andcellcycle arrest islargely
independent of MMR; however, cell killing remains to be
dependent on MMR (33). This observation can be explained
by either (i) MMR function as DNA damage sensors of high
density O
6meG/C in DNA and direct signaling or (ii) pro-
cessing of O
6meG/C initiated, unprocessed AP sites.
The hypothesis of direct signaling suggests a more direct
involvement of MMR proteins in the induction and recruit-
ment of proapoptotic proteins in response to DNA damage
and the initiation of apoptosis. MMR proteins can contribute
to replication fork blockage, or the block of transcription or
repair. A prediction of this model is that the repair function of
the proteins would not be requiredfor the damage-induced cell
death. Several pieces of evidence support this hypothesis for
the processing of cisplatin. A repair-deﬁcient mutation in
MSH6 was shown to retain wild-type response to several
chemotherapeutic agents (15,34). R. Fishel suggested that
the ‘sliding clamp model’ supports an ATP-dependent, direct
signaling mechanism (35).
We [(4), F. Salsbury, J. Clodfelter, M. Gentry, T. Hollis and
K. Drotschmann, manuscript in preparation)] and others (14)
were able to identify separation-of-function mutations in
MSH2 that distinguish damage response from repair. The
data presented here support this earlier observation. Here,
we demonstrate that single point mutations in MSH2 can affect
repair or cisplatin sensitivity, but not necessarily both. This
separation-of-function suggests a repair-independent mechan-
ism of cell death signaling by MMR proteins. Whether this is
true for different types of damage remains to be determined.
The MSH2 missense mutations are homologous to muta-
tions identiﬁed in tumors with suggestions for a causative
effect on carcinogenesis. Other mutations were described as
genetic variations in the general population. Our data demon-
strate that such single point mutations can contribute to gen-
ome instability, a prerequisite for carcinogenesis, or increased
cell survival after cisplatin exposure, a prerequisite for failure
of chemotherapy and clonal expansion of mutant cells. The
lack of a correlation between both phenotypes requires know-
ledge of the individual effects for applicability in the clinical
setting, with the goal to improve the efﬁcacy of chemotherapy.
Clonal selection of clones that are not initial mutators will be
observed after cisplatin treatment. If these clones promote a
drug-induced mutator phenotype, even primary cancers that
are not suggestive of MMR defects will be at risk for second-
ary carcinogenesis. The association of chemotolerance with
cisplatin-induced genome instability that is promoted by these
point mutations cautions about the treatment of tumors of
certain genetic backgrounds with chemotherapeutic agents.
Whether the effects are transferable to the treatment with
chemotherapeutics other than cisplatin remains to be determ-
ined. Current literature suggests differential MMR-dependent
cell death in dependence of the nature and dose of damage.
A comparison to the response to other drugs is underway.
The observation that mutations that were described as gen-
etic variations in the general population can promote increased
cell survival after cisplatin exposure, suggests that the pres-
ence of such polymorphisms will modulate the individual’s
capacity to process exposure to DNA damage. This may be
potentially importantfortheexposuretotherapeutic,aswellas
environmental agents.
Taken together, we demonstrate here that tumor-derived, as
well as polymorphic missense mutations in MSH2 can alter
cisplatin cytotoxicity and result in a tolerance phenotype that
is independent of an effect on genome stability. This chemo-
tolerance can be associated with a drug-induced mutator
phenotype that signiﬁcantly increases the initial mutation
rate. Data presented here have important implications for
the treatment of cancers with single point mutations in a
MMR protein and the prevention of tolerance and secondary
carcinogenesis. In addition, our results caution that the pres-
ence of polymorphic mutations with unknown functional con-
sequences may signiﬁcantly alter the response to clinical and
environmental mutagens.
ACKNOWLEDGEMENTS
The authors thank Dr Fred Perrino for valuable comments on
the manuscript. This work was supported by the Kulynych
Interdisciplinary Cancer Research Fund, NCI CA101829 and
the Comprehensive Cancer Center of WFUBMC. Funding to
pay the Open Access publication charges for this article was
provided by the Comprehensive Cancer Center of WFUBMC.
Conflict of interest statement. None declared.
REFERENCES
1. Jacob,S. and Praz,F. (2002) DNA MMR defects: role in colorectal
carcinogenesis. Biochimie, 84, 27–47.
2. Stojic,L., Brun,R. and Jiricny,J. (2004) Mismatch repair and DNA
damage signalling. DNA Repair, 3, 1091–1101.
3. Moggs,J.G., Szymkowski,D.E., Yamada,M., Karran,P. and Wood,R.D.
(1997) Differential human nucleotide excision repair of paired and
mispaired cisplatin-DNA adducts. Nucleic Acids Res., 25, 480–491.
4. Drotschmann,K.,Topping,R.P.,Clodfelter,J.E.andSalsbury,F.R.(2004)
Mutations in the nucleotide-binding motif of MutS homologs uncouple
cell death from cell survival. DNA Repair, 1, 743–753.
5. Karran,P., Offman,J. and Bignami,M. (2003) Human mismatch repair,
drug-induced DNA damage, and secondary cancer. Biochimie, 85,
1149–1160.
6. Drotschmann,K., Clark,A.B. and Kunkel,T.A. (1999) Mutator
phenotypes of common polymorphisms and missense mutations in
MSH2. Curr. Biol., 9, 907–910.
7. Konishi,M., Kikuchi-Yanoshita,R., Tanaka,K., Muraoka,M., Onda,A.,
Okumura,Y., Kishi,N., Iwama,T., Mori,T., Koike,M. et al., (1996)
Molecular nature of colon tumors in hereditary nonpolyposis colon
cancer, familial polyposis, and sporadic colon cancer. Gastroenterology,
111, 307–317.
8. Mohrenweiser,H.W., Xi,T., Vazquez-Matias,J. and Jones,I.M. (2002)
Identification of 127 amino acid substitution variants in screening
Nucleic Acids Research, 2005, Vol. 33, No. 10 332937 DNA repair genes in humans. Cancer Epidemiol. Biomarkers Prev.,
11, 1054–1064.
9. Obmolova,G., Bam,C., Hsieh,P. and Yang,W. (2000) Crystal structures
of MMR protein MutS and its complex with a substrate DNA. Nature,
407, 703–710.
10. Leach,F.S.,Nicolaides,N.C.,Papadopoulos,N.,Liu,B.,Jen,J.,Parsons,R.,
Peltomaki,P., Sistonen,P., Aaltonen,L.A. and Nystrom-Lahti,M. (1993)
Mutations of a mutS homolog in hereditary nonpolyposis colorectal
cancer. Cell, 75, 1215–1225.
11. Liu,B., Parsons,R.E., Hamilton,S.R., Petersen,G.M., Lynch,H.T.,
Watson,P., Markowitz,S., Willson,J.K., Green,J. and de la Chapelle,A.
(1994) hMSH2 mutations in hereditary nonpolyposis colorectal cancer
kindreds. Cancer Res., 54, 4590–4594.
12. Orth,K., Hung,J., Gazdar,A., Bowcock,A., Mathis,J.M. and Sambrook,J.
(1994) Genetic instability in human ovarian cancer cell lines. Proc. Natl
Acad. Sci. USA, 91, 9495–9499.
13. Marsischky,G.T., Filosi,N., Kane,M.F. and Kolodner,R. (1996)
Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in
MSH2-dependent mismatch repair. Genes Dev., 10, 407–420.
14. Lin,D.P., Wang,Y., Scherer,S.J., Clark,A.B., Yang,K., Avdievich,E.,
Jin,B., Werling,U., Parris,T., Kurihara,N. et al. (2004) An Msh2 point
mutation uncouples DNA mismatch repair and apoptosis. Cancer Res.,
64, 517–522.
15. Yang,G., Scherer,S.J., Shell,S.S., Yang,K., Kim,M., Lipkin,M.,
Kucherlapati,R., Kolodner,R.D. and Edelmann,W. (2004) Dominant
effects of an Msh6 missense mutation on DNA repair and cancer
susceptibility. Cancer Cell, 6, 139–150.
16. Fink,D.,Nebel,S.,Aebi,S.,Zheng,H.,Cenni,B.,Nehme,A.,Christen,R.D.
and Howell,S.B. (1996) The role of DNA MMR in platinum drug
resistance. Cancer Res., 56, 4881–4886.
17. Aebi,S., Kurdi-Haidar,B., Gordon,R., Cenni,B., Zheng,H., Fink,D.,
Christen,R.D., Boland,C.R., Koi,M., Fishel,R. and Howell,S.B. (1996)
Loss of DNA MMR in acquired resistance to cisplatin. Cancer Res.,
56, 3087–3090.
18. Drummond,J.T., Anthoney,A., Brown,R. and Modrich,P. (1996)
Cisplatin and adriamycin resistance are associated with MutLa and
MMR deficiency in an ovarian tumor cell line. J. Biol. Chem., 21,
19645–19648.
19. Fink,D., Nebel,S., Norris,P.S., Baergen,R.N., Wilczynski,S.P.,
Costa,M.J., Haas,M., Cannistra,S.A. and Howell,S.B. (1998)
Enrichment for DNA mismatch-repair deficient cells during treatment
with cisplatin. Intl. J. Cancer, 77, 741–746.
20. Glaab,W.E., Risinger,J.I., Umar,A., Barrett,J.C., Kunkel,T.A. and
Tindall,K.R. (1998) Cellular resistance and hypermutability in
mismatch repair-deficient human cancer cell lines following treatment
with methyl methanesulfonate. Mutat. Res., 398, 197–207.
21. Glaab,W.E., Risinger,J.I., Umar,A., Barrett,J.C., Kunkel,T.A. and
Tindall,K.R. (1998) Resistance to 6-thioguanine in mismatch
repair-deficient human cancer cell lines correlates with an increase in
induced mutations at the HPRT locus. Carcinogenesis, 19, 1931–1937.
22. Glaab,W.E., Tindall,K.R. and Skopek,T.R. (1999) Specificity of
mutations induced by methyl methanesulfonate in mismatch
repair-deficient human cancer cell lines. Mutat. Res., 427, 67–78.
23. Calmann,M.A., Nowosielska,A. and Marinus,M.G. (2005) Separation of
mutation avoidance and antirecombination functions in an Escherichia
coli mutS mutant. Nucleic Acids Res., 33, 1193–1200.
24. Vaisman,A., Varchenko,M., Umar,A., Kunkel,T.A., Risinger,J.I.,
Barrett,J.C.,Hamilton,T.C.andChaney,S.G.(1998)TheroleofhMLH1,
hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance:
correlation with replicative bypass of platinum–DNA adducts.
Cancer Res., 58, 3579–3585.
25. Bassett,E., Vaisman,A., Tropea,K.A., McCall,C.M., Masutani,C.,
Hanaoka,F. and Chaney,S.G. (2002) Frameshifts and deletions during
in vitro translesion synthesispast Pt–DNAadductsby DNA polymerases
beta and eta. DNA Repair, 1, 1003–1016.
26. Hoffmann,J.-S., Pillaire,M.-J., Garcia-Estefania,D., Lapalu,S. and
Villani,G. (1996) In vitro bypass replication of the cisplatin-d(GpG)
lesion by calf thymus DNA polymerase and human immunodeficiency
virus type I reverse transcriptase is highly mutagenic. J. Biol. Chem.,
271, 15386–15392.
27. Bassett,E.,King,N.M.,Bryant,M.F.,Hector,S.,Pendyala,L.,Chaney,S.G.
and Cordeiro-Stone,M. (2004) The role of DNA polymerase eta in
translesion synthesis past platinum–DNA adducts in human fibroblasts.
Cancer Res., 64, 6469–6475.
28. Zhang,H., Marra,G., Jiricny,J., Maher,V.M. and McCormick,J.J. (2000)
Mismatch repair is required for O
6-methylguanine-induced
homologous recombination in human fibroblasts. Carcinogenesis, 21,
1639–1646.
29. Durant,S.T., Morris,M.M., Illand,M., McKay,H.J., McCormick,C.,
Hirst,G.L., Borts,R.H. and Brown,R. (1998) Dependence on RAD52
and RAD1 for anticancer drug resistance mediated by inactivation of
mismatch repair genes. Curr. Biol., 9, 51–54.
30. Vernole,P., Pepponi,R. and D’Atri,S. (2003) Role of mismatch repair
in the induction of chromosomal aberrations and sister chromatid
exchangesincellstreatedwithdifferentchemotherapeuticagents.Cancer
Chemother. Pharmacol., 52, 185–192.
31. Nowosielska,A., Calmann,M.A., Zdraveski,Z., Essigmann,J.M. and
Marinus,M.G. (2004) Spontaneous and cisplatin-induced recombination
in Escherichia coli. DNA Repair, 3, 719–728.
32. Junop,M.S.,Yang,W.,Funchain,P.,Clendenin,W.andMiller,J.H.(2003)
In vitro and in vivo studies of MutS, MutL and MutH mutants:
correlation of mismatch repair and DNA recombination. DNA repair, 2,
387–405.
33. Stojic,L., Cejka,P. and Jiricny,J. (2005) High doses of SN1 type
methylating agents activate DNA damage signaling cascades that
are largely independent of mismatch repair. Cell cycle, 4,
e37–e41.
34. Kat,A., Thilly,W.G., Fang,W.-H., Longley,M.J., Li,G.-M. and
Modrich,P. (1993) An alkylation-tolerant, mutator human cell line is
deficient in strand-specific mismatch repair. Proc. Natl Acad. Sci. USA,
90, 6424–6428.
35. Fishel,R. (1999) Signaling mismatch repair in cancer. Nature Med., 5,
1239–1241.
36. Lamers,M.H., Perrakis,A., Enzlin,J.H., Winterwerp,H.H.K., de Wind,N.
andSixma,T.K.(2000)ThecrystalstructureofDNAMMRproteinMutS
binding to a GT mismatch. Nature, 407, 711–717.
3330 Nucleic Acids Research, 2005, Vol. 33, No. 10